Eli Lilly and Company (ETR: LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 634.97B |
| Revenue (ttm) | 36.64B |
| Net Income (ttm) | 7.50B |
| Shares Out | n/a |
| EPS (ttm) | 8.29 |
| PE Ratio | 84.61 |
| Forward PE | n/a |
| Dividend | 4.82 (0.69%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 3,801 |
| Average Volume | 3,305 |
| Open | 702.60 |
| Previous Close | 719.60 |
| Day's Range | 693.60 - 706.90 |
| 52-Week Range | 568.00 - 885.30 |
| Beta | 0.43 |
| RSI | 36.45 |
| Earnings Date | Jan 31, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the comp... [Read more]
Financial Performance
In 2023, Eli Lilly and Company's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial numbers in USD Financial StatementsNews
Should You Buy the Dip in Eli Lilly Stock Right Now?
Shares of pharmaceutical stock Eli Lilly are cratering after the company lowered its sales guidance for Q4.
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Dr. Kavita Patel talks impact of GLP-1 price negotiations
Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers.
Ozempic, Wegovy among drugs subject to Medicare price controls
The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.
Novo Nordisk Stumbles as Eli Lilly Tightens Grip on the Obesity Drug Market
Novo Nordisk Stumbles as Eli Lilly Tightens Grip on the Obesity Drug Market
BofA spotlights four bulls and two bears: LLY, TGT, PYPL, MCK, AR, and EWBC
Technology rallies as healthcare retreats: Exploring today's market dynamics
Sector Overview Today, the U.S. stock market showcases a remarkable resurgence in the technology sector, juxtaposed against a noticeable pullback in healthcare. Leading the tech charge are giants like...
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Eli Lilly's Options: A Look at What the Big Money is Thinking
Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE: LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...
Jim Cramer names a drug stock that could be the best for 2025, and it's not Eli Lilly
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
Eli Lilly (NYSE: LLY) has outperformed the market over the past 15 years by 10.74% on an annualized basis producing an average annual return of 22.68%. Currently, Eli Lilly has a market capitalizatio...
Tech sector rebounds while auto manufacturers struggle
Sector Overview Today's stock market heatmap reveals a striking contrast in sector performances. The technology sector shows signs of strength, with notable gains, while the auto manufacturing sector ...
US FDA approves expanded use of Lilly's bowel disease drug
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease.
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical remiss...
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical remiss...
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here's why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company's prior guidance and includes $3.5...
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Just before the JP Morgan healthcare conference , Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth c...
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Just before the JP Morgan healthcare conference, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth co...
Bond yield relief boosts 2 portfolio stocks plus, a check on Eli Lilly after Tuesday's slide
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly (NYSE:LLY) has become the industry leader in a class of drugs called gl...
Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly
Eli Lilly stock has been struggling since mid-August and could provide a nice bearish candidate.
Buy, Sell, Or Hold LLY Stock At $750?
Eli Lilly stock (NYSE: LLY) fell over 6% on Tuesday, January 14, after it announced that the sales of its obesity drugs are seeing slower than anticipated growth. It has adjusted its Q4 revenue foreca...